ERAP1 and colitis: These findings highlight the critical role of ERAP1 in modulating neutrophil-mediated immune responses and suggest that ERAP1 haploinsufficiency may compromise the therapeutic efficacy of anti-inflammatory agents such as sulfasalazine in colitis.